°®¶¹´«Ã½

Bacterial infections: Alfredo Torres, Ph.D., describes how his lab is developing vaccines against pathogenic E. coli and how the method can be applied to Burkholderia infections.

COVID-19: Kizzmekia Corbett, Ph.D., of the NIH's COVID-19 Response Team discusses her role in the development and testing of a spike-encoding mRNA vaccine for coronavirus. 

Dengue: Stephen Thomas, M.D., explores the latest research on the mosquito-borne illness dengue and dengue vaccine development. 

Fungal disease: The rise of antifungal resistance has made treatment of fungal diseases increasingly difficult. Scientists are exploring tactics for generating vaccines against common fungal pathogens. 

Human immunodeficiency virus: Dan Barouch, M.D., Ph.D., lays out the unique challenges of developing an HIV vaccine and discusses the ongoing clinical trial with an adenovirus-based vaccine developed in his lab.

Human papillomavirus: Doug Lowy, M.D., explains how research of bovine papillomavirus led to the development of an HPV vaccine. 

Influenza: There are now several "universal" flu vaccine candidates in clinical trials that aim to provide broader and longer-lasting influenza protection.​ 

Malaria: Malaria is one of humanity’s oldest foes. What will it take to defeat it? New vaccines, coupled with other preventive tactics, will be key. 

Measles: Measles and similar epidemics can arise in populations even where most people have been vaccinated, in part, due to a false sense the disease has been eliminated. Addressing misconceptions is the first step to ammending this.

Mpox: Reeti Khare, Ph.D., answers questions about the mpox (formerly called monkeypox) outbreak and how the smallpox vaccine can offer partial protection against the virus.

Pertussis: Unlike other childhood vaccine preventable diseases, the number of cases of pertussis have increased since the 1980s. The reasons for this increase are complex.

Plague: A new mRNA vaccine protects mice from the infection by Yersinia pestis, the bacterium that causes plague. What do the findings mean for the development of antibacterial mRNA vaccines?

Polio: Both the inactivated polio vaccine and oral polio vaccines have been instrumental in polio control efforts but have limitations that scientists are working to overcome. 

Tick-borne disease: TWiM discusses an mRNA vaccine that induces antibodies against tick proteins and prevents transmission of the Lyme disease agent, Borrelia burgdorferi.

Yellow Fever: Derick Kimathi, Ph.D., is investigating the safety and efficacy of using smaller doses of yellow fever vaccine to induce similar immunologic protection as standard dose. 

Vaccine Hesitancy

​Vaccines Are Critical. Here’s How You Can Help Spread the Word:
Many are not skeptical of vaccines because of science, but due to a wide variety of reasons—and therefore science alone does not always change minds. Learn how to spread the word about the value of vaccines and combat misinformation. 

Vaccine Equity

COVID-19 Vaccinations in Underrepresented Communities: While there are many barriers—from the historical burdens of underrepresented populations to accessibility and affordability of care—there are also tangible approaches to help make healthcare more equitable for all.

ASM Calls for Equity in Vaccine Distribution: ASM advocates for supplemental funding to CDC for vaccines, testing, contact tracing and mitigation to underserved communities and communities of color to ensure equity in pandemic response. 

Paul Offit joins TWiV to discuss all things vaccine, including how COVID-19 vaccine development was accelerated, whether the vaccines are safe and efficacious, the difference between an EUA and a licensed vaccine, sterilizing immunity, herd immunity and much more.